Program1

Indication

Discovery

Preclinical

Phase 1 Safety
Dose-Escalation

Phase 1b
Dose-Expansion/
Efficacy Signal

AB928 (Dual Adenosine Receptor Antagonist) LEARN MORE

AB928 + AB122 (anti-PD-1)

CRPC, RCC

Title

88%

AB928 + AB122 + Carbo/Pem

NSCLC

Title

65%

AB928 + mFOLFOX

CRC

Title

88%

AB928 + PLD2

TNBC

Title

88%

AB928 + PLD+ IPI-5493

TNBC

Title

65%

AB680 (Small Molecule CD73 Inhibitor) LEARN MORE

AB680 + AB122 + Gem/nab-paclitaxel

Pancreatic

Title

65%

AB122 (Anti-PD-1 Antibody) LEARN MORE

AB122 monotherapy

Biomarker-selected
(tumor-type agnostic)

Title

88%

AB154 (Anti-TIGIT Antibody) LEARN MORE

AB154 + AB122

Solid Tumors

Title

65%

Discovery and Preclinical Small Molecules

AB610 (PI3Kγ Inhibitor)

Oncology Indications

Title

22%

HIF-2α Antagonist

Oncology Indications

Title

18%

Axl Inhibitor

Oncology Indications

Title

13%

PAK4 Inhibitor

Oncology Indications

Title

13%
  1. Taiho has an option to Arcus’s programs in Japan and certain other Asian territories (excluding China) over a 5-year term.
  2. Pegylated liposomal doxorubicin.
  3. Clinical collaboration with Infinity Pharmaceuticals (IPI-549).